NORMOCARB HF 25 Drug Patent Profile
✉ Email this page to a colleague
When do Normocarb Hf 25 patents expire, and when can generic versions of Normocarb Hf 25 launch?
Normocarb Hf 25 is a drug marketed by Dialysis Sups and is included in one NDA. There is one patent protecting this drug.
This drug has four patent family members in four countries.
The generic ingredient in NORMOCARB HF 25 is magnesium chloride; sodium bicarbonate; sodium chloride. There are one hundred and forty-six drug master file entries for this compound. Additional details are available on the magnesium chloride; sodium bicarbonate; sodium chloride profile page.
DrugPatentWatch® Generic Entry Outlook for Normocarb Hf 25
By analyzing the patents and regulatory protections it appears that the earliest date
for generic entry will be March 4, 2023. This may change due to patent challenges or generic licensing.
Indicators of Generic Entry
Summary for NORMOCARB HF 25
| International Patents: | 4 |
| US Patents: | 1 |
| Applicants: | 1 |
| NDAs: | 1 |
| Formulation / Manufacturing: | see details |
| DailyMed Link: | NORMOCARB HF 25 at DailyMed |
DrugPatentWatch® Estimated Generic Entry Opportunity Date for NORMOCARB HF 25
Generic Entry Date for NORMOCARB HF 25*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
SOLUTION;INJECTION |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Anatomical Therapeutic Chemical (ATC) Classes for NORMOCARB HF 25
US Patents and Regulatory Information for NORMOCARB HF 25
NORMOCARB HF 25 is protected by one US patents.
Based on analysis by DrugPatentWatch, the earliest date for a generic version of NORMOCARB HF 25 is See Plans and Pricing.
This potential generic entry date is based on patent See Plans and Pricing.
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
Patents protecting NORMOCARB HF 25
Sterile low bicarbonate dialysis concentrate solutions
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: USE AS REPLACEMENT SOLUTION, HEMOFILTRATION SOLUTION OR HEMODIAFILTRATION SOLUTION IN CONTINUOUS RENAL REPLACEMENT THERAPY
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dialysis Sups | NORMOCARB HF 25 | magnesium chloride; sodium bicarbonate; sodium chloride | SOLUTION;INJECTION | 021910-001 | Jul 26, 2006 | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | Y | See Plans and Pricing | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for NORMOCARB HF 25
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Dialysis Sups | NORMOCARB HF 25 | magnesium chloride; sodium bicarbonate; sodium chloride | SOLUTION;INJECTION | 021910-001 | Jul 26, 2006 | See Plans and Pricing | See Plans and Pricing |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for NORMOCARB HF 25
See the table below for patents covering NORMOCARB HF 25 around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Canada | 2365787 | SOLUTIONS CONCENTREES STERILES FAIBLES EN BICARBONATE POUR DIALYSE (STERILE LOW BICARBONATE DIALYSIS CONCENTRATE SOLUTIONS) | See Plans and Pricing |
| European Patent Office | 1347795 | See Plans and Pricing | |
| World Intellectual Property Organization (WIPO) | 0249693 | See Plans and Pricing | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for NORMOCARB HF 25
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0984957 | 2012/048 | Ireland | See Plans and Pricing | PRODUCT NAME: A COMBINATION PRODUCT COMPRISING ASPIRIN AND ESOMEPRAZOLE MAGNESIUM TRIHYDRATE; NAT REGISTRATION NO/DATE: PA 970/063/001 20120831; FIRST REGISTRATION NO/DATE: 5402359; 5402367 5402375 20110812 |
| 0984957 | C300517 | Netherlands | See Plans and Pricing | PRODUCT NAME: ACETYLSALICYLZUUR EN ESOMEPRAZOLMAGNESIUMTRIHYDRAAT; NAT. REGISTRATION NO/DATE: RVG 107516 20110912; FIRST REGISTRATION: 540235954023675402375 2011120812 |
| 0984957 | 122012000017 | Germany | See Plans and Pricing | PRODUCT NAME: ASPIRIN UND ESOMEPRAZOL - MAGNESIUM-TRIHYDRAT; NAT. REGISTRATION NO/DATE: 81047.00.00 20110930 FIRST REGISTRATION: PORTUGAL 5402359 5402367 5402375 20110812 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2022 - 2023
NCE-1 Patent Challenge Dates 2022 - 2023
ClinicalTrialExchange - Connecting volunteers and trials
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2022, www.DrugPatentWatch.com.
Follow DrugPatentWatch:
